Jiangsu H鞥R UI medicine co., Ltd.
To assess the relative bioavailability of SHR7280 dry suspension and tablets in healthy subjects. To assess the safety and tolerability of a single dose of SHR7280 dry suspension and tablets.
Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction
SHR7280 tablets
SHR7280 dry suspension
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 16 participants |
Masking : | None (Open Label) |
Primary Purpose : | Basic Science |
Official Title : | Clinical Studies Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets (Single-center, Randomized, Open-label, Crossover) |
Actual Study Start Date : | May 23, 2023 |
Estimated Primary Completion Date : | June 9, 2023 |
Estimated Study Completion Date : | October 20, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment group ARM 1 SHR7280 dry suspension then SHR7280 tablets |
Drug: SHR7280 tablets Drug: SHR7280 dry suspension |
Experimental: Treatment group ARM 2 SHR 7280 tablets, then SHR 7280 dry suspension |
Drug: SHR7280 tablets Drug: SHR7280 dry suspension |
Ages Eligible for Study: | 18 Years to 45 Years |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 511447